Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) announced that it will proceed with a 1-for-20 reverse stock sp...
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, has released its financial results for ...
Net sales up organically by 3.8% to € 5.3 billion EBITDA pre up organically by 16.9% to € 1.6 billion EBITDA ...
TAE Life Sciences (TLS), a leader in boron neutron capture therapy (BNCT) technology, and Stella Pharma, the pioneering developer of the boronophenylalan...
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hyd...
Financial report for the period 1 January 2024 to 30 September 2024 &nb...
Illumina, Inc. shared its financial results for the third quarter of fiscal year 2024, demonstrating resilience amidst macroeconomic challenges and...
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24%compared to the third quarter of 2023 Placed seven Growth Direct&...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced financial r...
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 milli...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 28, ...
© 2024 Biopharma Boardroom. All Rights Reserved.
